Wednesday, November 08, 2023 8:01:18 AM
https://ih.advfn.com/stock-market/NASDAQ/immatics-nv-IMTX/stock-news/92498872/form-6-k-report-of-foreign-issuer-rules-13a-16
EXCERPT 1:
Development path for IMA203 GEN1 and IMA203CD8 GEN2 monotherapies
The goal of Immatics’ development strategy is to make its cell therapies targeting PRAME available to the broadest possible solid cancer patient population with an initial focus on the US market. To achieve this, Immatics has announced a three-step development strategy for leveraging the full breadth of PRAME, a target that is highly expressed in various solid cancers.
1. Focus on IMA203 GEN1 in cutaneous melanoma (potentially bundled with uveal melanoma), targeted to enter a registration-enabling Phase 2 clinical trial in 2024. Discussions with FDA to align on patient population, clinical trial design and CMC aspects are ongoing under the RMAT designation achieved for IMA203 GEN1 in multiple cancer types including cutaneous and uveal melanoma. There are up to 3,300 HLA-A*02 and PRAME-positive cutaneous and
Immatics Press Release November 8, 2023 5 | 8
uveal melanoma last-line patients per year in the US. A next update on the clinical development plan is expected in the first quarter of 2024.
2. In parallel, commence dedicated dose expansion cohorts for signal finding in ovarian and uterine cancer, preferentially with IMA203CD8 GEN2. Enrollment of patients with these cancer types is already ongoing. There are up to 9,000 HLA-A*02 and PRAME-positive ovarian and uterine last-line cancer patients per year in the US.
3. The development of a broader tumor-agnostic label in PRAME+ solid cancers, including in NSCLC, triple-negative breast cancer, and others. This could leverage the full potential of PRAME across multiple solid cancer types.
Recent IMTX News
- Immatics Announces Full Year 2023 Financial Results and Corporate Update • GlobeNewswire Inc. • 03/21/2024 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/22/2024 05:52:26 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/19/2024 01:58:09 PM
- Immatics Announces Pricing of $175 Million Public Offering • GlobeNewswire Inc. • 01/18/2024 01:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/17/2024 09:11:11 PM
- Immatics Announces Proposed Public Offering • GlobeNewswire Inc. • 01/17/2024 09:01:00 PM
- DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing • PR Newswire (US) • 01/16/2024 09:06:00 AM
- DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing • PR Newswire (US) • 01/16/2024 08:59:00 AM
- Levicept Appoints Eliot Forster as CEO • GlobeNewswire Inc. • 11/30/2023 09:00:00 AM
- Immatics Announces Third Quarter 2023 Financial Results and Business Update • GlobeNewswire Inc. • 11/14/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/08/2023 12:30:38 PM
- Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial • GlobeNewswire Inc. • 11/08/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/24/2023 11:10:46 AM
- Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy • GlobeNewswire Inc. • 10/24/2023 11:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/14/2023 04:15:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 09/13/2023 09:03:44 PM
- Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics • GlobeNewswire Inc. • 09/11/2023 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/11/2023 10:33:54 AM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 08/25/2023 08:11:30 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/17/2023 11:05:17 AM
- Immatics Announces Second Quarter 2023 Financial Results and Business Update • GlobeNewswire Inc. • 08/17/2023 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/10/2023 11:08:24 AM
- Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors • GlobeNewswire Inc. • 08/10/2023 11:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/24/2023 11:15:55 AM
- Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb • GlobeNewswire Inc. • 07/24/2023 11:00:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM